Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with diverse phenotypic and genetic expression, clinical presentation, and natural history. HCM has been recognized for 55 years, but recently substantial advances in diagnosis and treatment options have evolved, as well as increased recognition of the disease in clinical practice.
techniques, resulting in low-risk surgery that is highly effective in abolishing outflow obstruction and heart failure (HF) symptoms (10, 13, 36) ; 7) introduction of nonsurgical alternatives to myectomy for selected patients, such as percutaneous alcohol septal ablation (37); 8) recognition of the impact of patient age in dictating clinical course and management decisions (38); 9) publication of comprehensive guidelines offering concise and specific recommendations to the practicing community for diagnosis and management (39, 40) ; 10) advances in refractory HF treatment, including transplantation (18); 11) recognizing the significant cardiovascular mortality benefit attributable to contemporary treatment options (27, 28, 41) ; and 12) evolution in the perception of HCM to a disease deserving of a more optimistic outlook, compatible with extended longevity for most patients and affording them with a measure of reassurance (42) .
These advances for patients with HCM support this State-of-the-Art review, which is designed to provide the cardiovascular community with an opportunity to appreciate the important current approaches to this complex disease. This is a clinically relevant, patient care-related discussion formulated around contemporary HCM practice patterns, assembled by the efforts of 6 expert cardiologists with established dedication to HCM and care of these patients. The presentation is structured around 7 major areas: epidemiology; genetics and genetic testing; clinical diagnosis with imaging; natural history and impact of therapy; risk stratification and prevention of SD; HF management, septal reduction therapy, and transplantation; and the role and significance of atrial fibrillation (AF).
HCM remains a challenging disease, characterized by a heterogeneous clinical profile and considerable unpredictability in its natural history, with clinical decisions often made without absolute certainty on the basis of incomplete data.
EPIDEMIOLOGY
Although once considered rare, HCM is now more appropriately regarded as the most common inherited cardiac disease. A number of population studies estimate the prevalence of HCM in the general population to be at least 1 in 500, with the extrapolation that 700,000 Americans are affected by this disease (43) .
HCM is a global disease, reported in >50 countries on all continents, including the most populous nations of India and China (7) . Consequently, HCM is known to occur in a variety of races and ethnic groups (44) , as well as equally in both sexes and with a generally similar clinical, phenotypic, and genetic expression (45) .
Paradoxically, the estimated prevalence of HCM in the general population seems inconsistent with the persistent perception in cardiovascular practice that it is a distinctly uncommon disease. This apparent discrepancy strongly suggests that most affected individuals are not diagnosed clinically, probably achieving advanced longevity without HCM-related symptoms. Therefore, clinicians assess only a small fraction of the overall HCM population (likened to the "tip of the iceberg"), which often includes patients who are diagnosed only because of symptoms or clinical events (46) . Fortuitous diagnosis of HCM during routine clinical or family screening and evaluation is increasing due to unexpected findings on electrocardiography (ECG) or advanced imaging (47) .
GENETICS
GENERAL PRINCIPLES. It has been almost 25 years since the seminal work by the Seidman laboratory and others identified the first sarcomere gene mutations that cause HCM, bringing this genetic disease into the modern era of molecular investigation (25) . HCM is inherited with an autosomal dominant Mendelian pattern, variable expressivity, and age-related (and incomplete) penetrance (12, 25, (48) (49) (50) . Offspring of an affected individual have a 50% probability of inheriting a mutation and risk for the disease; alternatively, sporadic cases may be due to de novo mutations present in the proband, but which are absent in the parents (12, 25, (48) (49) (50) .
To date, a large number of genetic studies have established that HCM is caused by mutations in 11 or more genes encoding thick and thin contractile myofilament protein components of the sarcomere, or adjacent Z-disc, which are expressed primarily or exclusively in the heart (12, 25, (48) (49) (50) (Fig. 2) .
Approximately, 70% of successfully genotyped patients are found to have mutations in the 2 most common genes, beta-myosin heavy chain and myosin-binding protein C, whereas several other genes are much less common, accounting for <5% of patients (Fig. 2) .
The genetic heterogeneity of HCM has proved daunting, now with more than 1,500 individual mutations (90% missense mutations) identified among the known genes, most of which appear to be "private" and unique to individual families (12, 25) .
This vast genetic heterogeneity of HCM, perhaps more than any other factor, has limited the role of mutational analysis in predicting prognosis (or phenotypic expression) for individual patients (Central Illustration).
GENETIC TESTING RESULTS. Although initially confined to research settings, numerous commercial laboratories and academic centers now offer comprehensive (usually fee-for-service) genetic testing panels using rapid and automated DNA-sequencing to identify HCM-causing mutations and provide a molecular diagnosis (12) . Despite early optimism that "malignant" or "benign" mutations would be identifiable among patient populations (25) , more recent clinical genetic studies have shown that using single nucleotide sarcomere mutations to judge prognosis or predict outcome is unreliable for individual patients (4, 12, 40) . Therefore, genetic testing in HCM does not influence treatment strategies and specifically does not identify high-risk patients who may benefit from ICD therapy (4, 12, 27, 28, 40) . C l i n i c a l u t i l i t y o f g e n e t i c t e s t i n g . The most compelling reason to specifically consider genetic testing in clinical practice is to identify family members affected by HCM, but without left ventricular hypertrophy (LVH), who nevertheless may be at risk for developing this disease (Central Illustration).
Notably, in practical terms, the genetic testing screening strategy requires successful identification of a pathogenic (disease-causing) sarcomere mutation in a clinically expressed HCM proband. However, the likelihood that a pathogenic mutation will be found in the proband is only 35% overall (although somewhat higher with positive family history) (4, 12, (48) (49) (50) .
When a pathogenic mutation is identified in a family member, the genetic status of all other relatives can be interrogated; those who did not inherit the genetic abnormality found in the proband have a very low risk for developing the disease (4, 12) . (4, 9) . Since the early 1970s, echocardiography has been the mainstay for imaging the HCM phenotype (63) , and it remains the initial test for patients due to its portability, widespread access, and reliability in quantifying dynamic outflow tract gradients (62).
More recently, CMR has emerged as a powerful complementary tool due to its unique strengths of tomographic imaging and enhanced spatial resolution, which affords better characterization of the complex HCM phenotype. Specifically, CMR provides an opportunity to provide more precise LV wall thickness measurements and improved risk stratification by imaging myocardial scars (i.e., late gadolinium enhancement) (35) (Fig. 1) . In selected patients, CMR may be the sole method for reliably confirming the HCM phenotype and diagnosis, particularly when increased wall thickness is confined to specific areas of the LV chamber, such as the anterolateral free wall and apex (9, 64) . Underestimation of LV wall thickness by echocardiography (with respect to CMR) may have management implications (9) , particularly in patients with massive LVH, which is an independent SD risk factor in HCM (65) . 
Contemporary HCM programs effectively overestimated the risk of HCM (73) , contributing to the reputation of this disease as one with a grim prognosis and little expectation for longevity, a myth that may still persist today.
In the 1990s, reports from patient cohorts characterized by less selectivity, adjusted expected HCM mortality rates to about 1.5%/year (14) . However, by utilizing contemporary and aggressive treatment interventions (particularly the ICD and heart trans- 
RISK STRATIFICATION
Since the initial description of HCM, including the first contemporary report of an autopsy-based series (1), SD has been recognized as a devastating but unpredictable disease consequence; therefore, it becomes a crucial consideration in advising patients about their prognosis. Although a highly visible disease feature, SD is nevertheless confined to a relatively small subset of patients within the broad disease spectrum, most commonly young people through mid-life. SD usually occurs without premonitory warning signs or symptoms, but not uncommonly is associated with vigorous physical activity (4, 8, 39, 40) .
Recognition that the mechanism of SD in HCM is primary ventricular tachycardia and/or ventricular fibrillation (27) , with the application of ICDs to this disease almost 15 years ago (27) , has created the opportunity to prevent these catastrophic events for the first time. Therefore, the importance of risk stratification models to predict which individual patients would benefit most from device therapy has become increasingly relevant. Despite these limitations, the HCM risk stratification algorithm currently in use for primary prevention has proved effective in identifying most patients who will benefit from ICD therapy by relying largely on 5 major risk markers (4, 6, 8, 39, 40, 65, 76, 77) (Fig. 3) . Of note, the risk prediction model used in adult HCM patients is not easily translated to children, although a marked degree of LVH or syncope have proved the most reliable markers in this age group (29) . Some investigators have stratified the likelihood of SD by simple arithmetic summing of risk factors, or sophisticated mathematical modeling. These approaches still require broad-based validation (20, 32) .
Because HCM encompasses a particularly diverse spectrum, other small high-risk patient subsets (i.e., LV apical aneurysms [19] with regional scarring or end-stage with LV systolic dysfunction) (18) may justify consideration for primary prevention ICDs (Fig. 3) . Disease features, such as marked LV outflow obstruction at rest or diffuse LVH with wall thickness approaching 30 mm (27,32,33), can serve as "gray zone modifiers" or arbitrators for ICD decision making on a case-by-case basis when assessment is ambiguous using conventional markers. Engagement in intense competitive sports is a modifiable SD risk factor, even in the absence of other markers, leading to disqualification to reduce risk, as recommended by Bethesda Conference #36 (57) . Conversely, SD risk is proportional to the amount of LGE, with $15% (of LV mass) equivalent to a 2-fold risk compared to patients without LGE (35) . Extensive
LGE is a marker of SD risk, even among patients otherwise considered at low risk and who do not have established markers, but nevertheless can benefit from primary prevention ICD therapy (35) .
In addition, results of contrast-enhanced CMR can resolve complex ICD decisions when the level of SD risk remains uncertain after standard stratification; that is, supporting an ICD when extensive LGE is present and constituting evidence against an ICD when LGE is absent or focal (35) . Extensive LGE also prospectively identifies HCM patients who will develop adverse LV remodeling and progress to the end stage with systolic dysfunction (35) . Therefore, CMR has emerged as a powerful addition to the HCM armamentarium, justifying a role in routine assessment of these patients by strengthening the risk stratification model. However, drug treatment with aldosterone inhibitors (i.e., spironolactone) does not appear to blunt development or progression of myocardial fibrosis in HCM (78) .
IMPACT OF ICD IN PREVENTION OF SD
There is no evidence that drugs administered prophylactically (e.g., beta-blockers or verapamil) prevent SD in HCM (27) (28) (29) (30) (31) . The ICD is the only treatment strategy shown to prolong life in HCM due to its potential to reliably interrupt lifethreatening ventricular tachyarrhythmias, and prevent sudden and unexpected death (4, (27) (28) (29) (30) (31) 39, 40) (Central Illustration). In HCM, the ICD is effective despite substantial LVH, outflow obstruction, diastolic dysfunction, and microvascular ischemia (4, 9, 11, 16, 21, 36, 62, 65, 79, 80) .
Much of the available data on ICDs comes from an international multicenter registry of >500 HCM patients, in which the rate of device interventions appropriately terminating ventricular tachycardia and/or ventricular fibrillation was 4%/year for primary prevention (cumulative, 25% over 5 years), largely in asymptomatic patients, and 11%/year for secondary prevention after cardiac arrest (28) (Fig. 3 ). These effective rates are similar to those reported from numerous other centers in Europe, Australia, and the United States (30, 31, 34) . Furthermore, defibrillator intervention rates were similar in >200 children and/or adolescents with HCM who underwent implantation for primary or secondary prevention at <20 years of age (29) . An exception to ICD efficacy is in LAMP2 patients, who are usually refractory to defibrillation (55) . (Fig. 4) . Outflow gradients are characteristically dynamic, with spontaneous variability influenced by altered myocardial contractility and loading conditions (2,4,11,16,21,39,40 ). (4, 10, 40) . Operative mortality for septal myectomy is now <1% at experienced centers (10), and the documented benefits of myectomy provide patients with the opportunity to achieve good quality of life, extended longevity, and survival similar to that in the general population (36) (Fig. 4) .
Percutaneous alcohol septal ablation has become an alternative to surgical myectomy (37, (101) (102) (103) (104) (105) in selected patients (39, 40) . Factors that influence the decision to proceed with alcohol ablation include advanced age, significant comorbidity that increases surgical risk, or the strong desire of patients to avoid open-heart surgery (40).
Alcohol ablation reduces LV outflow gradient (and symptoms) by creating a large basal ventricular septal infarction (10% of the LV wall, 30% of the septum, on average) by infusion of absolute alcohol into a major septal perforator coronary artery (106) (Fig. 4) . In contrast, myectomy requires resection of a small Contemporary HCM amount of muscle from the basal septum, but without intramyocardial scarring (10, 39, 40) . Ablation data derived from some retrospective studies show shortterm survival (with respect to all-cause mortality) to be similar to myectomy and in also age-and sex-matched general populations. Procedural mortality, low in experienced myectomy programs (4, 10, 13, 36, 39, 40) , is similar for both interventions when performed at HCM centers (37).
However, important differences between the septal Individual patients may be subject to disease progression along 1 or more of these complication pathways, each of which is associated with potentially effective treatment options. Alternatively, most HCM patients probably experience a benign course without requiring major interventions. AF ¼ atrial fibrillation; other abbreviations as in Figures 1 and 2 . East 28th Street, Suite 620, Minneapolis, Minnesota 55407. E-mail: hcm.maron@mhif.org.
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